Evidence map›Paper›PMID 19700757›Full record

ArticleThe American journal of pathology2009

A key role for the integrin alpha2beta1 in experimental and developmental angiogenesis.

James D San Antonio, Jason J Zoeller, Kari Habursky, Kevin Turner, Wittaya Pimtong, Michelle Burrows, Sungwook Choi, Sandeep Basra, Joel S Bennett, William F DeGrado and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 75 citations in OpenAlex.

  1. Glycocalyx and basal lamina in neurological disorders.Matrix biology : journal of the International Society for Matrix Biology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Integrin αJournal of nanobiotechnology · 2021
    Article
  11. A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy.Matrix biology : journal of the International Society for Matrix Biology · 2021
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. A current view of perlecan in physiology and pathology: A mosaic of functions.Matrix biology : journal of the International Society for Matrix Biology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

James D San AntonioDepartment of Pathology, Anatomy and Cell Biology, 1020 Locust Street, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Jason J Zoeller
Kari Habursky
Kevin Turner
Wittaya Pimtong
Michelle Burrows
Sungwook Choi
Sandeep Basra
Joel S Bennett
William F DeGrado
Renato V Iozzo
Thomas Jefferson University · USUniversity of Pennsylvania · USSidney Kimmel Cancer Center · US

Funding

STUDIES OF PLATELET ADHERENCE TO OSTEOPONTINP01HL062250 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1999 to 2013
$28.4M
Alcohol Tissue InjuryT32AA007463 · NIAAA · THOMAS JEFFERSON UNIVERSITY · PI HOEK, JOANNES B, VADIGEPALLI, RAJANIKANTH · 1985 to 2021
$9.1M
NEOPLASTIC MODULATION OF PROTEOGLYCAN METABOLISMR01CA039481 · NCI · UNIVERSITY OF PENNSYLVANIA · PI IOZZO, RENATO V. · 1985 to 2020
$7.1M
The Biology of Perlecan in Cancer and AngiogenesisR01CA047282 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 1990 to 2019
$5.7M
MECHANISMS OF ENDOTHELIAL CELL-COLLAGEN INTERACTIONSR01HL053590 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI SANANTONIO, JAMES D · 2003 to 2007
$1.4M
Natural EGFR Antagonists and CancerR01CA120975 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 2007 to 2010
$942k
NCI NIH HHS R01 CA039481NCI NIH HHS R01 CA047282NCI NIH HHS R01 CA120975NCI NIH HHS R01 CA39481NCI NIH HHS R01 CA47282NHLBI NIH HHS P01 HL062250NHLBI NIH HHS R01 HL053590NHLBI NIH HHS R01 HL53590NHLBI NIH HHS R01 HL62250NIAAA NIH HHS T32 AA007463NIAAA NIH HHS T32 AA07463
6 · The paper itself

Abstract

The alpha2beta1 integrin receptor plays a key role in angiogenesis. Here we investigated the effects of small molecule inhibitors (SMIs) designed to disrupt integrin alpha2 I or beta1 I-like domain function on angiogenesis. In unchallenged endothelial cells, fibrillar collagen induced robust capillary morphogenesis. In contrast, tube formation was significantly reduced by SMI496, a beta1 I-like domain inhibitor and by function-blocking anti-alpha2beta1 but not -alpha1beta1 antibodies. Endothelial cells bound fluorescein-labeled collagen I fibrils, an interaction specifically inhibited by SMI496. Moreover, SMI496 caused cell retraction and cytoskeletal collapse of endothelial cells as well as delayed endothelial cell wound healing. SMI activities were examined in vivo by supplementing the growth medium of zebrafish embryos expressing green fluorescent protein under the control of the vascular endothelial growth factor receptor-2 promoter. SMI496, but not a control compound, interfered with angiogenesis in vivo by reversibly inhibiting sprouting from the axial vessels. We further characterized zebrafish alpha2 integrin and discovered that this integrin is highly conserved, especially the I domain. Notably, a similar vascular phenotype was induced by morpholino-mediated knockdown of the integrin alpha2 subunit. By live videomicroscopy, we confirmed that the vessels were largely nonfunctional in the absence of alpha2beta1 integrin. Collectively, our results provide strong biochemical and genetic evidence of a central role for alpha2beta1 integrin in experimental and developmental angiogenesis.

Indexed as

AnimalsAnimals, Genetically ModifiedAntibodies, BlockingCell AdhesionCell MovementCells, CulturedCollagenDipeptidesEndothelium, VascularHumansIntegrin alpha2beta1Neovascularization, PhysiologicProtein Structure, TertiaryVascular Endothelial Growth Factor Receptor-2ZebrafishAntibodies, BlockingCollagenDipeptidesIntegrin alpha2beta1SMI496Vascular Endothelial Growth Factor Receptor-2

Identifiers

PMID19700757
PMCPMC2731151
OpenAlexW2150296205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.